Nano-antibiotics in chronic lung infection therapy against Pseudomonas aeruginosa

Colloids and Surfaces B: Biointerfaces

Volumn 116, Issue , 2014, Pages 772-785

  Hadinoto, Kunn ^a   Cheow, Wean Sin ^a  

^a Nanyang Technological University   (Singapore)

Author keywords

Cystic fibrosis; Drug nanoparticles; Liposomes; Mucus barrier; Pulmonary biofilm

Indexed keywords

BACTERIA; BIOFILMS; BODY FLUIDS; LIPOSOMES; NANOPARTICLES; POLYMERS; PULMONARY DISEASES;

ANTIBIOTIC RELEASE; CHRONIC OBSTRUCTIVE PULMONARY DISEASE; CYSTIC FIBROSIS; DRUG NANO PARTICLES; MUCUS BARRIER; PHYSICO-CHEMICAL STABILITY; POLYMER NANOPARTICLES; PSEUDOMONAS AERUGINOSA;

ANTIBIOTICS;

AMIKACIN; ANTIBIOTIC AGENT; ARIKACE; CIPROFLOXACIN; LIPOQUIN; LIPOSOME; NANOPARTICLE; POLYMER; POLYMYXIN B; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TOBRAMYCIN; UNCLASSIFIED DRUG; ANTIINFECTIVE AGENT;

ANTIBACTERIAL ACTIVITY; BRONCHIECTASIS; DOSAGE SCHEDULE COMPARISON; DRUG EFFICACY; DRUG FORMULATION; DRUG STABILITY; HUMAN; HYDROPHOBICITY; IN VITRO STUDY; IN VIVO STUDY; LIPOSOMAL DELIVERY; LUNG INFECTION; NANOENCAPSULATION; NANOPHARMACEUTICS; PARTICLE SIZE; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTION; REVIEW; SURFACE CHARGE; CHEMISTRY; CHRONIC DISEASE; DOSE RESPONSE; DRUG EFFECTS; MICROBIAL SENSITIVITY TEST; PSEUDOMONAS INFECTIONS; STRUCTURE ACTIVITY RELATION;

ANTI-BACTERIAL AGENTS; CHRONIC DISEASE; DOSE-RESPONSE RELATIONSHIP, DRUG; MICROBIAL SENSITIVITY TESTS; NANOPARTICLES; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84898795265     PISSN: 09277765     EISSN: 18734367     Source Type: Journal    
DOI: 10.1016/j.colsurfb.2014.02.032     Document Type: Review

References (119)

1. Pauwels R.A., Rabe K.F. Burden and clinical features of chronic obstructive pulmonary disease (COPD). Lancet 2004, 364:613-620.
2. Patel I.S., Vlahos I., Wilkinson T.M.A., Lloyd-Owen S.J., Donaldson G.C., Wilks M., Reznek R.H., Wedzicha J.A. Bronchiectasis, exacerbation indices, and inflammation in chronic obstructive pulmonary disease. A.J. Resp. Crit. Care 2004, 170:400-407.
3. O'Donnell A.E. Bronchiectasis. Chest 2008, 134:815-823.
4. Kobayashi H., Kobayashi O., Kawai S. Pathogenesis and clinical manifestations of chronic colonization by Pseudomonas aeruginosa and its biofilms in the airway tract. J. Infect. Chemother. 2009, 15:125-142.
5. Ho P.L., Chan K.N., Ip M.S.M., Lam W.K., Ho C.S., Yuen K.Y., Tsang K.W.T. The effect of Pseudomonas aeruginosa infection on clinical parameters in steady-state bronchiectasis. Chest 1998, 114:1594-1598.
6. Martinez-Garcia M.A., Soler-Cataluna J.J., Perpina-Tordera M., Romain-Sanchez P., Soriano J. Factors associated with lung function decline in adult patients with stable non-cystic fibrosis bronchiectasis. Chest 2007, 132:1565-1572.
7. Pritt B., O'Brien L., Winn W. Mucoid Pseudomonas in cystic fibrosis. Am. J. Clin. Pathol. 2007, 128:32-34.
8. Lin S.H., Kuo P.H., Hsueh P.R., Yang P.C., Kuo S.H. Sputum bacteriology in hospitalized patients with acute exacerbation of chronic obstructive pulmonary disease in Taiwan with an emphasis on Klebsiella pneumoniae and Pseudomonas aeruginosa. Respirology 2007, 12:81-87.
9. Martinez-Solano L., Macia M.D., Fajardo A., Oliver A., Martinez J.L. Chronic Pseudomonas aeruginosa infection in chronic obstructive pulmonary disease. Clin. Infect. Dis. 2008, 47:1526-1533.
10. Murphy T.F., Brauer A.L., Eschberger K., Lobbins P., Grove L., Cai X.Y., Sethi S. Pseudomonas aeruginosa in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2008, 177:853-860.
11. Vendrell M., de Gracia J., Olveira C., Martinez M.A., Giron R., Maiz L., Canton R., Coll R., Escribano A., Sole A. Diagnosis and treatment of bronchiectasis. Arch. Bronconeumol. 2008, 44:629-640.
12. Hoiby N. Antibiotic-therapy for chronic infection of Pseudomonas in the lung. Annu. Rev. Med. 1993, 44:1-10.
13. Hoiby N. Recent advances in the treatment of Pseudomonas aeruginosa infections in cystic fibrosis. BMC Med. 2011, 9.
14. Prayle A.P., Smyth A.R. From pipeline to patient: new developments in cystic fibrosis therapeutics. Expert Opin. Pharmacother. 2013, 14:323-329.
15. Ryan G., Singh M., Dwan K. Inhaled antibiotics for long-term therapy in cystic fibrosis. Cochrane Database Syst. Rev. 2011.
16. Stewart P.S. Mechanisms of antibiotic resistance in bacterial biofilms. Int. J. Med. Microbiol. 2002, 292:107-113.
17. Costerton W., Veeh R., Shirtliff M., Pasmore M., Post C., Ehrlich G. The application of biofilm science to the study and control of chronic bacterial infections. J. Clin. Invest. 2003, 112:1466-1477.
18. Delcour A.H. Outer membrane permeability and antibiotic resistance. Biochim. Biophys. Proteins Proteom. 2009, 1794:808-816.
19. Lambert P.A. Mechanisms of antibiotic resistance in Pseudomonas aeruginosa. J. R. Soc. Med. 2002, 95:22-26.
20. Anderson G.G., O'Toole G.A. Innate and induced resistance mechanisms of bacterial biofilms. Bacterial Biofilms 2008, 322:85-105.
21. Omri A., Beaulac C., Bouhajib M., Montplaisir S., Sharkawi M., Lagace J. Pulmonary retention of free and liposome encapsulated tobramycin after intratracheal administration in uninfected rats and rats infected with Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 1994, 38:1090-1095.
22. Hunt B.E., Weber A., Berger A., Ramsey B., Smith A.L. Macromolecular mechanisms of sputum inhibition of tobramycin activity. Antimicrob. Agents Chemother. 1995, 39:34-39.
23. Adi H., Young P.M., Chan H.K., Agus H., Traini D. Co-spray-dried mannitol-ciprofloxacin dry powder inhaler formulation for cystic fibrosis and chronic obstructive pulmonary disease. Eur. J. Pharm. Sci. 2010, 40:239-247.
24. Hassett D.J., Sutton M.D., Schurr M.J., Herr A.B., Caldwell C.C., Matu J.O. Pseudomonas aeruginosa hypoxic or anaerobic biofilm infections within cystic fibrosis airways. Trends Microbiol. 2009, 17:130-138.
25. Landry R.M., An D.D., Hupp J.T., Singh P.K., Parsek M.R. Mucin-Pseudomonas aeruginosa interactions promote biofilm formation and antibiotic resistance. Mol. Microbiol. 2006, 59:142-151.
26. Herrmann G., Yang L.A., Wu H., Song Z.J., Wang H.Z., Hoiby N., Ulrich M., Molin S., Riethmuller J., Doring G. Colistin-tobramycin combinations are superior to monotherapy concerning the killing of biofilm Pseudomonas aeruginosa. J. Infect. Dis. 2010, 202:1585-1592.
27. Geller D.E., Pitlick W.H., Nardella P.A., Tracewell W.G., Ramsey B.W. Pharmacokinetics and bioavailability of aerosolized tobramycin in cystic fibrosis. Chest 2002, 122:219-226.
28. Prayle A., Smyth A.R. Aminoglycoside use in cystic fibrosis: therapeutic strategies and toxicity. Curr. Opin. Pulm. Med. 2010, 16:604-610.
29. Cheer S.M., Waugh J., Noble S. Inhaled tobramycin (TOBI (R))-a review of its use in the management of Pseudomonas aeruginosa infections in patients with cystic fibrosis. Drugs 2003, 63:2501-2520.
30. Dal Negro R., Micheletto C., Tognella S., Visconti M., Turati C. Tobramycin nebulizer solution in severe COPD patients colonized with Pseudomonas aeruginosa: effects on bronchial inflammation. Adv. Ther. 2008, 25:1019-1030.
31. Drobnic M.E., Sune P., Montoro J.B., Ferrer A., Orriols R. Inhaled tobramycin in non-cystic fibrosis patients with bronchiectasis and chronic bronchial infection with Pseudomonas aeruginosa. Ann. Pharmacother. 2005, 39:39-44.
32. Merlo C.A., Boyle M.P., Diener-West M., Marshall B.C., Goss C.H., Lechtzin N. Incidence and risk factors for multiple antibiotic-resistant Pseudomonas aeruginosa in cystic fibrosis. Chest 2007, 132:562-568.
33. Pitt T.L., Sparrow M., Warner M., Stefanidou M. Survey of resistance of Pseudomonas aeruginosa from UK patients with cystic fibrosis to six commonly prescribed antimicrobial agents. Thorax 2003, 58:794-796.
34. Hoffman L.R., D'Argenio D.A., MacCoss M.J., Zhang Z.Y., Jones R.A., Miller S.I. Aminoglycoside antibiotics induce bacterial biofilm formation. Nature 2005, 436:1171-1175.
35. Nair C.G., Chao C., Ryall B., Williams H.D. Sub-lethal concentrations of antibiotics increase mutation frequency in the cystic fibrosis pathogen Pseudomonas aeruginosa. Lett. Appl. Microbiol. 2013, 56:149-154.
36. Tre-Hardy M., Traore H., El Manssouri N., Vanderbist F., Vaneechoutte M., Devleeschouwer M.J. Evaluation of long-term co-administration of tobramycin and clarithromycin in a mature biofilm model of cystic fibrosis clinical isolates of Pseudomonas aeruginosa. Int. J. Antimicrob. Agents 2009, 34:370-374.
37. MacLeod D.L., Velayudhan J., Kenney T.F., Therrien J.H., Sutherland J.L., Barker L.M., Baker W.R. Fosfomycin enhances the active transport of tobramycin in Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 2012, 56:1529-1538.
38. Yu Q.R., Griffin E.F., Moreau-Marquis S., Schwartzman J.D., Stanton B.A., O'Toole G.A. In vitro evaluation of tobramycin and aztreonam versus Pseudomonas aeruginosa biofilms on cystic fibrosis-derived human airway epithelial cells. J. Antimicrob. Chemother. 2012, 67:2673-2681.
39. Kumon H., Tomochika K., Matunaga T., Ogawa M., Ohmori H. A sandwich gun method for the penetration assay of antimicrobial agents through Pseudomonas exopolysaccharides. Microbiol. Immunol. 1994, 38:615-619.
40. Bilton D., Henig N., Morrissey B., Gotfried M. Addition of inhaled tobramycin to ciprofloxacin for acute exacerbations of Pseudomonas aeruginosa infection in adult bronchiectasis. Chest 2006, 130:1503-1510.
41. King P., Lomovskaya O., Griffith D.C., Burns J.L., Dudley M.N. In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis. Antimicrob. Agents Chemother. 2010, 54:143-148.
42. Geller D.E., Flume P.A., Griffith D.C., Morgan E., White D., Loutit J.S., Dudley M.N. Pharmacokinetics and safety of MP-376 (Levofloxacin Inhalation Solution) in cystic fibrosis subjects. Antimicrob. Agents Chemother. 2011, 55:2636-2640.
43. Wilson R., Welte T., Polverino E., De Soyza A., Greville H., O'Donnell A., Alder J., Reimnitz P., Hampel B. Ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis: a phase II randomised study. Eur. Respir. J. 2013, 41:1107-1115.
44. Yang Y., Tsifansky M.D., Wu C.J., Yang H.I., Schmidt G., Yeo Y. Inhalable antibiotic delivery using a dry powder co-delivering recombinant deoxyribonuclease and ciprofloxacin for treatment of cystic fibrosis. Pharm. Res. 2010, 27:151-160.
45. Zhao T.M., Liu Y.N. N-acetylcysteine inhibit biofilms produced by Pseudomonas aeruginosa. BMC Microbiol. 2010, 10.
46. Sanders N.N., De Smedt S.C., Van Rompaey E., Simoens P., De Baets F., Demeester J. Cystic fibrosis sputum-a barrier to the transport of nanospheres. Am. J. Respir. Crit. Care Med. 2000, 162:1905-1911.
47. Suk J.S., Lai S.K., Boylan N.J., Dawson M.R., Boyle M.P., Hanes J. Rapid transport of muco-inert nanoparticles in cystic fibrosis sputum treated with N-acetyl cysteine. Nanomedicine 2011, 6:365-375.
48. Forier K., Messiaen A.S., Raemdonck K., Deschout H., Rejman J., De Baets F., Nelis H., De Smedt S.C., Demeester J., Coenye T., Braeckmans K. Transport of nanoparticles in cystic fibrosis sputum and bacterial biofilms by single-particle tracking microscopy. Nanomedicine 2013, 8:935-949.
49. Meers P., Neville M., Malinin V., Scotto A.W., Sardaryan G., Kurumunda R., Mackinson C., James G., Fisher S., Perkins W.R. Biofilm penetration, triggered release and in vivo activity of inhaled liposomal amikacin in chronic Pseudomonas aeruginosa lung infections. J. Antimicrob. Chemother. 2008, 61:859-868.
50. Semmler-Behnke M., Takenaka S., Fertsch S., Wenk A., Seitz J., Mayer P., Oberdorster G., Kreyling W.G. Efficient elimination of inhaled nanoparticles from the alveolar region: evidence for interstitial uptake and subsequent reentrainment onto airway epithelium. Environ. Health Perspect. 2007, 115:728-733.
51. Hara K., Tsujimoto H., Tsukada Y., Huang C.C., Kawashima Y., Tsutsumi M. Histological examination of PLGA nanospheres for intratracheal drug administration. Int. J. Pharm. 2008, 356:267-273.
52. Weers J., Metzheiser B., Taylor G., Warren S., Meers P., Perkins W.R. A gamma scintigraphy study to investigate lung deposition and clearance of inhaled amikacin-loaded liposomes in healthy male volunteers. J. Aerosol Med. Pulm. Drug Deliv. 2009, 22:131-138.
53. Schiffelers R., Storm G., Bakker-Woudenberg I. Liposome-encapsulated aminoglycosides in pre-clinical and clinical studies. J. Antimicrob. Chemother. 2001, 48:333-344.
54. Alhajlan M., Alhariri M., Omri A. Efficacy and safety of liposomal clarithromycin and its effect on Pseudomonas aeruginosa virulence factors. Antimicrob. Agents Chemother. 2013, 57:2694-2704.
55. Lagace J., Dubreuil M., Montplaisir S. Liposome-encapsulated antibiotics-preparation, drug release, and antimicrobial activity against Pseudomonas aeruginosa. J. Microencapsul. 1991, 8:53-61.
56. Druis-Kawa Z., Dorotkiewicz-Jach A., Gubernator J., Gula G., Bocer T., Doroszkiewicz W. The interaction between Pseudomonas aeruginosa cells and cationic PC:Chol:DOTAP liposomal vesicles versus outer-membrane structure and envelope properties of bacterial cell. Int. J. Pharm. 2009, 367:211-219.
57. Serisier D.J., Bilton D., De Soyza A., Thomson P.J., Kolbe J., Greville H.W., Cipolla D., Bruinenberg P., Gonda I. Inhaled, dual release liposomal ciprofloxacin in non-cystic fibrosis bronchiectasis (ORBIT-2): a randomized, double-blind, placebo-controlled trial. Thorax 2013, 68:812-817. the ORBIT-2 investigators.
58. Okusanya O.O., Bhavnani S.M., Hammel J., Minic P., Dupont L.J., Forrest A., Mulder G.J., Mackinson C., Ambrose P.G., Gupta R. Pharmacokinetic and pharmacodynamic evaluation of liposomal amikacin for inhalation in cystic fibrosis patients with chronic pseudomonal infection. Antimicrob. Agents Chemother. 2009, 53:3847-3854.
59. Clancy J.P., Dupont L., Konstan M.W., Billings J., Fustik S., Goss C.H., Lymp J., Minic P., Quittner A.L., Rubenstein R.C., Young K.R., Saiman L., Burns J.L., Govan J.R.W., Ramsey B., Gupta R., Arikace Study G. Phase II studies of nebulised Arikace in CF patients with Pseudomonas aeruginosa infection. Thorax 2013, 68:818-825.
60. Suk J.S., Lai S.K., Wang Y.Y., Ensign L.M., Zeitlin P.L., Boyle M.P., Hanes J. The penetration of fresh undiluted sputum expectorated by cystic fibrosis patients by non-adhesive polymer nanoparticles. Biomaterials 2009, 30:2591-2597.
61. Cheow W.S., Hadinoto K. Enhancing encapsulation efficiency of highly water-soluble antibiotic in poly(lactic-co-glycolic acid) nanoparticles: modifications of standard nanoparticle preparation methods. Colloids Surf. Physicochem. Eng. Aspects 2010, 370:79-86.
62. Ungaro F., d'Angelo I., Coletta C., Bianca R.D.D., Sorrentino R., Perfetto B., Tufano M.A., Miro A., La Rotonda M.I., Quaglia F. Dry powders based on PLGA nanoparticles for pulmonary delivery of antibiotics: modulation of encapsulation efficiency, release rate and lung deposition pattern by hydrophilic polymers. J. Controlled Release 2012, 157:149-159.
63. Cheow W.S., Chang M.W., Hadinoto K. The roles of lipid in anti-biofilm efficacy of lipid-polymer hybrid nanoparticles encapsulating antibiotics. Colloids Surf., A 2011, 389:158-165.
64. Patil Y.P., Jadhav S. Novel methods for liposome preparation. Chem. Phys. Lipids 2014, 177:8-18.
65. Kita K., Dittrich C. Drug delivery vehicles with improved encapsulation efficiency: taking advantage of specific drug-carrier interactions. Expert Opin. Drug Deliv. 2011, 8:329-342.
66. Alhariri M., Azghani A., Omri A. Liposomal antibiotics for the treatment of infectious diseases. Expert Opin. Drug Deliv. 2013, 10:1515-1532.
67. Huh A.J., Kwon Y.J. "Nanoantibiotics": a new paradigm for treating infectious diseases using nanomaterials in the antibiotics resistant era. J. Controlled Release 2011, 156:128-145.
68. Yacoby I., Benhar I. Antibacterial nanomedicine. Nanomedicine 2008, 3:329-341.
69. Saude A.C.M., Cherobim M.D., Amaral A.C., Dias S.C., Franco O.L. Nanoformulated antibiotics: the next step for pathogenic bacteria control. Curr. Med. Chem. 2013, 20:1232-1240.
70. Seil J.T., Webster T.J. Antimicrobial applications of nanotechnology: methods and literature. Int. J. Nanomed. 2012, 7:2767-2781.
71. Sharma A., Arya D.K., Dua M., Chhatwal G.S., Johri A.K. Nano-technology for targeted drug delivery to combat antibiotic resistance. Expert Opin. Drug Del. 2012, 9:1325-1332.
72. Zhang L., Pornpattananangkul D., Hu C.M.J., Huang C.M. Development of nanoparticles for antimicrobial drug delivery. Curr. Med. Chem. 2010, 17:585-594.
73. Kalishwaralal K., BarathManiKanth S., Pandian S.R.K., Deepak V., Gurunathan S. Silver nanoparticles impede the biofilm formation by Pseudomonas aeruginosa and Staphylococcus epidermidis. Colloids Surf., B 2010, 79:340-344.
74. Alipour M., Suntres Z.E., Halwani M., Azghani A.O., Omri A. Activity and interactions of liposomal antibiotics in presence of polyanions and sputum of patients with cystic fibrosis. Plos One 2009, 4.
75. Halwani M., Hebert S., Suntres Z.E., Lafrenie R.M., Azghani A.O., Omri A. Bismuth-thiol incorporation enhances biological activities of liposomal tobramycin against bacterial biofilm and quorum sensing molecules production by Pseudomonas aeruginosa. Int. J. Pharm. 2009, 373:141-146.
76. Beaulac C., Sachetelli S., Lagace J. In-vitro bactericidal efficacy of sub-MIC concentrations of liposome-encapsulated antibiotic against Gram-negative and Gram-positive bacteria. J. Antimicrob. Chemother. 1998, 41:35-41.
77. Mugabe C., Azghani A.O., Omri A. Liposome-mediated gentamicin delivery: development and activity against resistant strains of Pseudomonas aeruginosa isolated from cystic fibrosis patients. J. Antimicrob. Chemother. 2005, 55:269-271.
78. Alipour M., Halwani M., Omri A., Suntres Z.E. Antimicrobial effectiveness of liposomal polymyxin B against resistant Gram-negative bacterial strains. Int. J. Pharm. 2008, 355:293-298.
79. Jia Y.M., Joly H., Omri A. Characterization of the interaction between liposomal formulations and Pseudomonas aeruginosa. J. Liposome Res. 2010, 20:134-146.
80. Omri A., Ravaoarinoro M. Preparation, properties and the effects of amikacin, netilmicin and tobramycin in free and liposomal formulations on Gram-negative and Gram-positive bacteria. Int. J. Antimicrob. Agents 1996, 7:9-14.
81. Drulis-Kawa Z., Gubernator J., Dorotkiewicz-Jach A., Doroszkiewicz W., Kozubek A. In vitro antimicrobial activity of liposomal meropenem against Pseudomonas aeruginosa strains. Int. J. Pharm. 2006, 315:59-66.
82. Gubernator J., Druis-Kawa Z., Dorotkiewicz-Jach A., Doroszkiewicz W., Kozubek A. In vitro antimicrobial activity of liposomes containing ciprofloxacin, meropenem and gentamicin against gram-negative clinical bacterial strains. Lett. Drug Des. Discov. 2007, 4:297-304.
83. Beaulac C., ClementMajor S., Hawari J., Lagace J. Eradication of mucoid Pseudomonas aeruginosa with fluid liposome-encapsulated tobramycin in an animal model of chronic pulmonary infection. Antimicrob. Agents Chemother. 1996, 40:665-669.
84. Beaulac C., ClementMajor S., Hawari J., Lagace J. In vitro kinetics of drug release and pulmonary retention of microencapsulated antibiotic in liposomal formulations in relation to the lipid composition. J. Microencapsul. 1997, 14:335-348.
85. Ma Y., Wang Z., Zhao W., Lu T., Wang R., Mei Q., Chen T. Enhanced bactericidal potency of nanoliposomes by modification of the fusion activity between liposomes and bacterium. Int. J. Nanomed. 2013, 8:2351-2360.
86. Sachetelli S., Beaulac C., Riffon R., Lagace J. Evaluation of the pulmonary and systemic immunogenicity of Fluidosomes, a fluid liposomal-tobramycin formulation for the treatment of chronic infections in lungs. Biochim. Biophys. Acta-Gen. Subj. 1999, 1428:334-340.
87. Marier J.F., Brazier J.L., Lavigne J., Ducharme M.P. Liposomal tobramycin against pulmonary infections of Pseudomonas aeruginosa: a pharmacokinetic and efficacy study following single and multiple intratracheal administrations in rats. J. Antimicrob. Chemother. 2003, 52:247-252.
88. Chattopadhyay S., Ehrman S.H., Bellare J., Venkataraman C. Morphology and bilayer integrity of small liposomes during aerosol generation by air-jet nebulisation. J. Nanopart. Res. 2012, 14.
89. Beaulac C., Sachetelli S., Lagace J. In vitro bactericidal evaluation of a low phase transition temperature liposomal tobramycin formulation as a dry powder preparation against gram negative and gram positive bacteria. J. Liposome Res. 1999, 9:301-312.
90. Beaulac C., Sachetelli S., Lagace J. Aerosolization of low phase transition temperature liposomal tobramycin as a dry powder in an animal model of chronic pulmonary infection caused by Pseudomonas aeruginosa. J. Drug Target. 1999, 7:33-41.
91. Cocera M., Lopez O., Coderch L., Parra J.L., de la Maza A. Permeability investigations of phospholipid liposomes by adding cholesterol. Colloids Surf., A 2003, 221:9-17.
92. Omri A., Suntres Z.E., Shek P.N. Enhanced activity of liposomal polymyxin B against Pseudomonas aeruginosa in a rat model of lung infection. Biochem. Pharmacol. 2002, 64:1407-1413.
93. Rukholm G., Mugabe C., Azghani A.O., Omri A. Antibacterial activity of liposomal gentamicin against Pseudomonas aeruginosa: a time-kill study. Int. J. Antimicrob. Agents 2006, 27:247-252.
94. Bakker-Woudenberg I., ten Kate M.T., Guo L., Working P., Mouton J.W. Ciprofloxacin in polyethylene glycol-coated liposomes: Efficacy in rat models of acute or chronic Pseudomonas aeruginosa infection. Antimicrob. Agents Chemother. 2002, 46:2575-2581.
95. Dawson M., Wirtz D., Hanes J. Enhanced viscoelasticity of human cystic fibrotic sputum correlates with increasing microheterogeneity in particle transport. J. Biol. Chem. 2003, 278:50393-50401.
96. Alipour M., Suntres Z.E., Omri A. Importance of DNase and alginate lyase for enhancing free and liposome encapsulated aminoglycoside activity against Pseudomonas aeruginosa. J. Antimicrob. Chemother. 2009, 64:317-325.
97. Zaru M., Mourtas S., Klepetsanis P., Fadda A.M., Antimisiaris S.G. Liposomes for drug delivery to the lungs by nebulization. Eur. J. Pharm. Biopharm. 2007, 67:655-666.
98. Huang C.T., Stewart P.S. Reduction of polysaccharide production in Pseudomonas aeruginosa biofilms by bismuth dimercaprol (BisBAL) treatment. J. Antimicrob. Chemother. 1999, 44:601-605.
99. Kaneko Y., Thoendel M., Olakanmi O., Britigan B.E., Singh P.K. The transition metal gallium disrupts Pseudomonas aeruginosa iron metabolism and has antimicrobial and antibiofilm activity. J. Clin. Invest. 2007, 117:877-888.
100. Halwani M., Yebio B., Suntres Z.E., Alipour M., Azghani A.O., Omri A. Co-encapsulation of gallium with gentamicin in liposomes enhances antimicrobial activity of gentamicin against Pseudomonas aeruginosa. J. Antimicrob. Chemother. 2008, 62:1291-1297.
101. Halwani M., Blomme S., Suntres Z.E., Alipour M., Azghani A.O., Kumar A., Omri A. Liposomal bismuth-ethanedithiol formulation enhances antimicrobial activity of tobramycin. Int. J. Pharm. 2008, 358:278-284.
102. Alhariri M., Omri A. Efficacy of liposomal bismuth-ethanedithiol-loaded tobramycin after intratracheal administration in rats with pulmonary Pseudomonas aeruginosa infection. Antimicrob. Agents Chemother. 2013, 57:569-578.
103. Alipour M., Suntres Z.E., Lafrenie R.M., Omri A. Attenuation of Pseudomonas aeruginosa virulence factors and biofilms by co-encapsulation of bismuth-ethanedithiol with tobramycin in liposomes. J. Antimicrob. Chemother. 2010, 65:684-693.
104. Alipour M., Dorval C., Suntres Z.E., Omri A. Bismuth-ethanedithiol incorporated in a liposome-loaded tobramycin formulation modulates the alginate levels in mucoid Pseudomonas aeruginosa. J. Pharm. Pharmacol. 2011, 63:999-1007.
105. Grit M., Crommelin J.A. Chemical stability of liposomes-implications for their physical stability. Chem. Phys. Lipids 1993, 64:3-18.
106. Elhissi A.M.A., Giebultowicz J., Stec A.A., Wroczynski P., Ahmed W., Alhnan M.A., Phoenix D., Taylor K.M.G. Nebulization of ultradeformable liposomes: the influence of aerosolization mechanism and formulation excipients. Int. J. Pharm. 2012, 436:519-526.
107. Chen C.J., Han D.D., Cai C.F., Tang X. An overview of liposome lyophilization and its future potential. J. Controlled Release 2010, 142:299-311.
108. Card J.W., Zeldin D.C., Bonner J.C., Nestmann E.R. Pulmonary applications and toxicity of engineered nanoparticles. Am. J. Physiol.-Lung Cell. Mol. Physiol. 2008, 295:L400-L411.
109. Broughton-Head V.J., Smith J.R., Shur J., Shute J.K. Actin limits enhancement of nanoparticle diffusion through cystic fibrosis sputum by mucolytics. Pulm. Pharmacol. Ther. 2007, 20:708-717.
110. Cheow W.S., Chang M.W., Hadinoto K. Antibacterial efficacy of inhalable antibiotic-encapsulated biodegradable polymeric nanoparticles against E. coli biofilm cells. J. Biomed. Nanotechnol. 2010, 6:391-403.
111. Sung J.C., Padilla D.J., Garcia-Contreras L., VerBerkmoes J.L., Durbin D., Peloquin C.A., Elbert K.J., Hickey A.J., Edwards D.A. Formulation and pharmacokinetics of self-assembled rifampicin nanoparticle systems for pulmonary delivery. Pharm. Res. 2009, 26:1847-1855.
112. Toti U.S., Guru B.R., Hali M., McPharlin C.M., Wykes S.M., Panyam J., Whittum-Hudson J.A. Targeted delivery of antibiotics to intracellular chlamydial infections using PLGA nanoparticles. Biomaterials 2011, 32:6606-6613.
113. Dillen K., Vandervoort J., Van den Mooter G., Verheyden L., Ludwig A. Factorial design, physicochemical characterisation and activity of ciprofloxacin-PLGA nanoparticles. Int. J. Pharm. 2004, 275:171-187.
114. Abdelghany S.M., Quinn D.J., Ingram R.J., Gilmore B.F., Donnelly R.F., Taggart C.C., Scott C.J. Gentamicin-loaded nanoparticles show improved antimicrobial effects towards Pseudomonas aeruginosa infection. Int. J. Nanomed. 2012, 7:4053-4063.
115. Hadinoto K., Sundaresan A., Cheow W.S. Lipid-polymer hybrid nanoparticles as a new generation therapeutic delivery platform: a review. Eur. J. Pharm. Biopharm. 2013, 10.1016/j.ejpb.2013.07.002.
116. Guo C.X., Liu S.Q., Jiang C., Li W.Y., Dai Z.F., Fritz H., Wu X.Y. A promising drug controlled-release system based on diacetylene/phospholipid polymerized vesicles. Langmuir 2009, 25:13114-13119.
117. Qin G.T., Li Z., Xia R.M., Li F., O'Neill B.E., Goodwin J.T., Khant H.A., Chiu W., Li K.C. Partially polymerized liposomes: stable against leakage yet capable of instantaneous release for remote controlled drug delivery. Nanotechnology 2011, 22.
118. Li J., He Y.Z., Li W., Shen Y.Z., Li Y.R., Wang Y.F. A novel polymer-lipid hybrid nanoparticle for efficient nonviral gene delivery. Acta Pharmacol. Sin. 2010, 31:509-514.
119. Cheow W.S., Hadinoto K. Green preparation of antibiotic nanoparticle complex as potential anti-biofilm therapeutics via self-assembly amphiphile-polyelectrolyte complexation with dextran sulfate. Colloids Surf., B 2012, 92:55-63.